US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Zai Lab Limited - American Depositary Shares
(NQ:
ZLAB
)
24.33
-1.17 (-4.59%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zai Lab Limited - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Brady, Airbnb, Insmed And Other Big Stocks Moving Higher On Tuesday
↗
September 05, 2023
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications
↗
September 05, 2023
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on...
Via
Benzinga
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
August 30, 2023
Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumors
From
Zai Lab Limited
Via
GlobeNewswire
Earnings Preview For Zai Lab
↗
August 04, 2023
Via
Benzinga
Why Is Schrödinger Stock Tumbling Today?
↗
August 03, 2023
Schrödinger Inc (NASDAQ: SDGR) shares are down after the company, on Wednesday,
Via
Benzinga
Zai Lab Limited (NASDAQ:ZLAB) Investor Notice: Investigation over Possible Violations of Securities Laws
↗
July 31, 2023
San Diego, CA -- (SBWIRE) -- 07/31/2023 -- Zai Lab Limited is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Zai Lab Announces Participation in September Investor Conferences
August 29, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Why Is Cancer Focused-Novocure's Stock Plunging Today?
↗
August 28, 2023
Novocure Ltd (NASDAQ: NVCR) shares are falling after the company's phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
↗
August 10, 2023
Via
Benzinga
Akamai Technologies, Array Technologies Music, HNI, PENN Entertainment And Other Big Stocks Moving Higher On Wednesday
↗
August 09, 2023
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
August 07, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Bowlero, and Chegg and Encourages Investors to Contact the Firm
August 06, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 26, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 21, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
July 20, 2023
- Company to Host Conference Call and Webcast on August 8, 2023, at 8:00 a.m. ET
From
Zai Lab Limited
Via
GlobeNewswire
JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
July 19, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
July 17, 2023
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...
Via
Benzinga
Why Are Argenx Shares Trading Higher Today?
↗
July 17, 2023
Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
July 17, 2023
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!
Via
InvestorPlace
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
July 17, 2023
U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 17, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 16, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer
July 14, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 10, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis
July 10, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
↗
July 08, 2023
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic...
Via
Talk Markets
Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer
July 06, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 05, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB
July 04, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB
July 03, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
